Tamil Nadu

Laila group is inviting applications from dedicated scientist to become a part of new innovative and exploratory research program for developing molecules/Nutraceuticals /Botanical drugs for unmet medical needs.

Nest Provides Professional licensing services in all the countries for Healthcare, allied and life science Professionals who intend to work in that country.
Nest can act a bridging source to guide, mentor, oversee you licensing process. It acts a facilitator / coordinator in your licensure documentation process etc.

Post: Pharmacist

Orinova, A cosmeceutical division of Origo Pharmaceuticals Pvt. Ltd. Orinova objective is - Discover the beauty. We believe in bringing super specialty innovative cosmeceuticals products for discovering the beauty from inside.

About Author:
Hiren Sakhiya,
M.Sc in Clinical Research Management,
Prist University, Thanjavur,
India
*sakhiyahiren@gmail.com

ABSTRACT
Diabetes a chronic (lifelong) disease marked by high levels of sugar in the blood. Diabetes is a common disease in older age, affecting about one in five individuals. In 2000, according to the World Health Organization, at least 171 million people worldwide suffer from diabetes, or 2.8% of the population. Its incidence is increasing rapidly, and it is estimated that by 2030, this number will almost double. Diabetes is also associated with mortality and significant morbidity, including neurological disability. Diabetes affects both peripheral nervous system and central nervous system. Neuropathy along with retinopathy and nephropathy appears in late stage of diabetes but effect on cognition starts in early stage of diabetes. Although the effects of diabetes on the peripheral nervous system are well established, the effects of diabetes on the central nervous system have been less clear. Several studies have found that diabetes is related to dementia and cognitive function. It is unclear in which stage of diabetes the cognitive decrements become manifest and how they progress over time. Study is conducted to confirm the association of cognitive function with diabetes.

About Authors:
Yamini Pendyala*, Sudha Talasila, M.sulthana
Department of Pharmaceutics,
Padmavathi College of Pharmacy and Research Institute,
Periyanahalli, Tamilnadu.
*Yamini.pendyala45@gmail.com

ABSTRACT
The purpose of this research was to formulate and systemically evaluate in-vitro and in-vivo performances of mucoadhesive Ramipril microspheres for its potential use in the treatment of hypertension, myocardial infraction. Ramipril mucoadhesive microspheres, containing chitosan as mucoadhesive polymer and ethyl cellulose as carrier polymer, were prepared by an emulsion-solvent evaporation technique. Preformulation studies were carried out before formulation design. Total seven formulations were prepared.Microspheres were discrete, spherical, free-flowing and showed a good percentage of drug entrapment efficiency. An in-vitro wash off test showed that Ramipril mucoadhesive microspheres adhered more strongly to the gastric mucous layer and could be retained in the gastrointestinal tract for an extended period of time. In-vitro dissolution test was carried out by using phosphate buffer pH 6.8. All the formulations showed good dissolution profiles. Among all the formulation F5 showed good dissolution profile with 81.0% of drug release in 12 hours. In-vitro release kinetic data of Ramipril microspheres showed that the drug release mechanism was diffusion controlled as the plots of Higuichi model was linear. All formulations exhibited Non-Fickian diffusion (n value is in between 0.5 to 1) mechanism. Stability studies were done for the selected formulation indicates that there is no change in drug content of the formulation.The results showed a sustained anti-hypertensive effect over a longer period of time in case of mucoadhesive microspheres, compared to the powder. In conclusion, the prolonged gastrointestinal residence time and slow release of Ramipril resulting from the mucoadhesive microspheres, could contribute to the provision of a sustained anti-hypertensive effect.

The National Dairy Development Board (NDDB) set up Indian Immunologicals Ltd. (IIL) in 1982 with the objective of making Foot and Mouth Disease (FMD) vaccine available to farmers at an affordable price. The technology for FMD vaccine manufacture was obtained from M/s. Wellcome Foundation Limited, United Kingdom. The plant in Hyderabad today has a capacity to make 80 million trivalent doses of FMD vaccine.

Axon Drugs is a thriving pharmaceutical company headquartered at Chennai, the southern Metropolitan city which has fast developed into a primary business destination in India. Axon started off with supply of medicines to Government Institutions in the form of tenders. Gradually, with this expertise Axon ventured into higher avenues.

“ELICO” The name which pioneered and gave new meaning and direction to the word Analytical Instrumentation in India and electronics in state of Andhra Pradesh, and this word “Electronics” has now become the identity of Hyderabad. The company commenced its operations in 1959 slightly more than a decade after Independence of Country. It was a time when there were very few players nationally in the technology arena and none locally.